Leadership ConfidenceThe lock-up agreement by leadership signals strong confidence in SynAct's strategy and commitment to long-term value creation, which can enhance investor trust and stability.

Pipeline ProgressAdvancement in clinical trials for Resomelagon indicates potential for successful treatment options in rheumatoid arthritis, strengthening SynAct's market position in the biotech industry.

Balance Sheet StrengthA low-leverage balance sheet offers SynAct financial flexibility, reducing risk and enabling strategic investments in R&D and potential partnerships.

Bears Say

No Revenue GenerationThe absence of revenue generation highlights SynAct's reliance on external funding, posing a risk to financial sustainability until successful commercialization of its products.

Negative Cash FlowPersistent negative cash flow indicates ongoing financial strain, necessitating external funding and potentially limiting SynAct's operational flexibility.

Ongoing LossesSustained operating losses reflect challenges in achieving profitability, impacting SynAct's ability to reinvest in growth and innovation without external capital.

SynAct Pharma AB News

SynAct Pharma Publishes 2025 Annual Results and Highlights R&D Focus

SynAct Pharma AB ( ($SE:SYNACT) ) has shared an update. SynAct Pharma has released its annual results for...

3d ago

SynAct Pharma Advances SEK 5 Million Share Buyback, Reacquires 212,307 Shares

The latest update is out from SynAct Pharma AB ( ($SE:SYNACT) ). SynAct Pharma AB has repurchased 212,307...

3d ago

SynAct Pharma Plans Capital Markets Day Ahead of Key Clinical Readouts

An announcement from SynAct Pharma AB ( ($SE:SYNACT) ) is now available. SynAct Pharma will host a Capital...

11d ago

SynAct Pharma Hits Recruitment Milestone in Phase 2b Rheumatoid Arthritis Trial

SynAct Pharma AB ( ($SE:SYNACT) ) just unveiled an announcement. SynAct Pharma has completed recruitment of 240 patients...

14d ago

SynAct Pharma Launches Phase 2 RESPIRE Trial of Resomelagon in Viral Respiratory Insufficiency

SynAct Pharma AB ( ($SE:SYNACT) ) has provided an update. SynAct Pharma has initiated a Phase 2 randomized,...

21d ago

SynAct Pharma Names Long-Serving Finance Executive as Interim CFO

SynAct Pharma AB ( ($SE:SYNACT) ) has provided an update. SynAct Pharma has appointed long-serving finance executive Malin...

1M ago

SynAct Pharma Launches Share Buyback to Optimize Capital Structure

SynAct Pharma AB ( ($SE:SYNACT) ) has shared an update. SynAct Pharma AB’s board has approved a share...

1M ago

SynAct Pharma Leadership Enters Lock-Up Ahead of Key Clinical Milestones

SynAct Pharma AB ( ($SE:SYNACT) ) just unveiled an update. SynAct Pharma’s board and management have voluntarily signed...

2M ago

SynAct Pharma Leadership Buys Shares as Key Rheumatoid Arthritis Milestone Nears

SynAct Pharma AB ( ($SE:SYNACT) ) has provided an update. SynAct Pharma AB announced that its top leadership,...

2M ago

SynAct Pharma AB Appoints Nomination Committee for 2026 AGM

An announcement from SynAct Pharma AB ( ($SE:SYNACT) ) is now available. SynAct Pharma AB has announced the...

2M ago

8F8 FAQ

What was SynAct Pharma AB’s price range in the past 12 months?

SynAct Pharma AB lowest stock price was €1.22 and its highest was €2.32 in the past 12 months.

What is SynAct Pharma AB’s market cap?

SynAct Pharma AB’s market cap is €95.55M.

When is SynAct Pharma AB’s upcoming earnings report date?

SynAct Pharma AB’s upcoming earnings report date is May 27, 2026 which is in 96 days.

How were SynAct Pharma AB’s earnings last quarter?

SynAct Pharma AB released its earnings results on Feb 18, 2026. The company reported -€0.04 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.04.

Is SynAct Pharma AB overvalued?

According to Wall Street analysts SynAct Pharma AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does SynAct Pharma AB pay dividends?

SynAct Pharma AB does not currently pay dividends.

What is SynAct Pharma AB’s EPS estimate?

SynAct Pharma AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does SynAct Pharma AB have?

SynAct Pharma AB has 53,330,242 shares outstanding.

What happened to SynAct Pharma AB’s price movement after its last earnings report?

SynAct Pharma AB reported an EPS of -€0.04 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of SynAct Pharma AB?

Currently, no hedge funds are holding shares in DE:8F8

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

SynAct Pharma AB

SynAct Pharma AB, through its subsidiary, SynAct Pharma ApS, develops medicines for acute deterioration in inflammatory diseases. The company is developing AP1189, a drug candidate for the treatment of rheumatoid arthritis and idiopathic membranous glomerulonephritis. It has a partnership with the University Of Örebro to study the reduction of inflammation in vascular disease. The company was founded in 2012 and is headquartered in Lund, Sweden.